

Ajanta Pharma Limited Ajanta Tower, 54-A, M V Road, Chakala, Andheri (E), Mumbai – 400 093, India

T +91 22 6060 9000 E legal.info@ajantapharma.com W www.ajantapharma.com



30th April 2025

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400001

National Stock Exchange of India, Exchange Plaza, 5th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Scrip Code: BSE – AJANTPHARM 532331

Scrip Code: NSE AJANTPHARM EQ

Sub.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Further to our letter of even date and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that at the Board meeting held on Wednesday, 30th April 2025, Board has also approved the following:

- 1. Re-appointment of Mr. Madhusudan B. Agrawal (DIN: 00073872) as Executive Director and Vice Chairman for a term of 5 years w.e.f 1st April 2025, subject to approval of members of the Company.
- 2. Re-appointment of M/s. Aneja Assurance Pvt. Ltd. as Internal Auditors of the Company for the financial year 2025-26.
- 3. Re-appointment of M/s. RA & Co., Cost Accountants (Firm Registration No: 000242), as Cost Auditors of the Company for the financial year 2025-26, subject to ratification of their remuneration by members of the Company.
- 4. Appointment of M/s. D.G. Prajapati & Associates, Company Secretaries, (FCS No. 6567; COP No. 4209), as Secretarial Auditors of the Company for one term of 5 consecutive years, subject to approval of members of the Company.
- 5. Re-appointment of M/s. R S Sanghai & Associates, Chartered Accountants, (Firm Registration no. (ICAI FRN 109094W) Mumbai as Tax Auditors of the Company for the financial year 2025-26.

Details with respect to the above, in terms of Regulation 30 read with Schedule III of the Listing Regulations and SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September 2015 is annexed herewith.

Kindly take the above on your records.

Thanking You,

Yours faithfully,

GAURANG SHAH

Sr. VP - Legal & Company Secretary

Encl:a/a

Ajanta Pharma Limited Ajanta Tower, 54-A, M V Road, Chakala, Andheri (E), Mumbai – 400 093, India

T +91 22 6060 9000 E legal.info@ajantapharma.com W www.ajantapharma.com



Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015.

1. Re-appointment of Mr. Madhusudan B. Agrawal as Executive Director and Vice Chairman

	T
Name of Director	Madhusudan Bhagwandas Agrawal
DIN No.	00073872
Reason for change	He is re-appointed for a period of 5 years, subject to approval of the members of the Company.
Date of re-appointment	Effective from 1 st April 2025.
Brief Profile	Mr. Madhusudan Agrawal is one of promoter director of the Company since inception and has contributed significantly for the growth and development of the Company. He has deep understanding of the Company's business operations, extensive knowledge of the pharma industry and is managing public relations, networking & liasioning and CSR initiatives.
Disclosure of relationship between Directors	Mr. Madhusudan B. Agrawal is the brother of Mr. Mannalal B. Agrawal (Chairman), and uncle of Mr. Yogesh M. Agrawal (Managing Director) and Mr. Rajesh M. Agrawal (Joint Managing Director).
Whether such director is debarred from holding office of director by SEBI or any other authority	No

2. Re-appointment of Internal Auditors

Disclosure requirement	Details
Reason for Change	They are re-appointed for FY 2026.
Date of re-appointment	30 th April 2025
Brief profile	Aneja Assurance Pvt. Ltd. is a Mumbai-based internal audit and risk advisory firm with over 40 years of experience. The firm specializes in internal audits, risk management, governance, and compliance services across sectors such as pharmaceuticals, BFSI, and manufacturing. Known for its strong audit methodologies and adherence to global standards, the firm is staffed by professionals including CAs, CIAs, and MBAs, and leverages advanced tools to deliver high-quality assurance services.
Disclosure of relationships	None
between directors and auditors	







Re-appointment of Cost Auditors

op ajanta pharma

Disclosure requirement	Details
Reason for Change	They are re-appointed as Cost Auditors for FY 2026, in accordance with the provisions of Section 148 of the Companies Act, 2013 and rules made thereunder.
Date of re-appointment	30 th April 2025
Brief profile	M/S RA & Co., Cost Accountants is a Cost & Management Consultancy firm rendering Professional Services across India since last three decades. Their Partners are having reach experience in the field.
Disclosure of relationships between directors and auditors	None

Appointment of Secretarial Auditor

Disclosure requirement	Details
Reason for Change	In order to bring in fresh perspective and methodology for the secretarial audit.
Date of Appointment	30 th April 2025 for a period of 5 years, subject to approval of members of the Company.
Brief profile	M/s. D.G. Prajapati & Associates (FCS No. 6567; COP No. 4209), have over 25 years of experience and expertise in Company Law, SEBI Regulations, FEMA, Corporate Restructuring and Secretarial Audits. They are a peer-reviewed firm.
Disclosure of relationships between directors and auditors	None

Re-appointment of Tax Auditor

Disclosure requirement	Details
Reason for Change	They are re-appointed as Tax Auditors for FY 2025-26.
Date of re-appointment	30 th April 2025
Brief profile	The Firm is having in-depth expertise in direct and indirect tax laws and enjoys the reputation of quality deliverables in an efficient and timely manner. The Firm is known for out of the box thinking that has resulted in providing path-breaking solutions.
Disclosure of relationships	None
between directors and auditors	